Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma

Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, Cheng Z, Ennis DP, Iyer N, McNamara S, Natoli M, Mason S
,
et al
No abstract available
Keywords:

32 Biomedical and Clinical Sciences

,

3211 Oncology and Carcinogenesis

,

3204 Immunology

,

Cancer

,

Rare Diseases

,

Ovarian Cancer

,

Genetics

,

Orphan Drug

,

Immunotherapy

,

Women's Health

,

5.1 Pharmaceuticals

,

2.1 Biological and endogenous factors

,

Cancer

,

Animals

,

Carcinoma, Ovarian Epithelial

,

Cystadenocarcinoma, Serous

,

Enhancer of Zeste Homolog 2 Protein

,

Epigenesis, Genetic

,

Humans

,

Immunity

,

Mice

,

Ovarian Neoplasms

,

Prognosis

,

Tumor Microenvironment